ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

On location

BTK Inhibitor LOXO-305 Shows Promise in Previously Treated Mantle Cell Lymphoma

In the phase I/II BRUIN trial that included patients with previously treated B-cell malignancies – particularly mantle cell lymphoma (MCL) – treatment with the...
On location

Avatrombopag Demonstrates Efficacy in ITP, Regardless of Prior Treatment

Treatment with the thrombopoietin receptor agonist (TPO-RA) avatrombopag led to durable platelet count responses in patients with immune thrombocytopenia (ITP), with responses among both...
On location

Big Ideas on Burnout: Trainees Propose System-Wide Solutions

The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –...
On location

Does High-Dose Methotrexate Protect the Central Nervous System in High-Risk DLBCL?

A retrospective study found that treatment with high-dose methotrexate did not lower the risk of central nervous system (CNS) relapse in patients with high-risk...
On location

New HOPE for Hemophilia B: One-Time Gene Therapy Abolishes Bleeding in Most Patients

A single dose of the gene therapy drug etranacogene dezaparvovec increased factor IX (FIX) activity levels, and eliminated the need for prophylactic FIX, in...
On location

Adding Mycophenolate to Corticosteroids Improves Response as Frontline ​Option in Immune Thrombocytopenia

In results from the randomized, controlled FLIGHT trial, patients with immune thrombocytopenia (ITP) who received mycophenolate mofetil (MMF) plus corticosteroids as first-line therapy were...
On location

Asciminib Beats Bosutinib in Treatment-Resistant Chronic Myeloid Leukemia

Asciminib, a first-in-class allosteric inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP), was more effective at achieving major molecular response (MMR) than bosutinib in...
On location

Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia Vera

PTG-300, a hepcidin mimetic, eliminated the need for phlebotomy and the resultant iron deficiency in patients with high- and low-risk polycythemia vera (PV), according...
On location

In Utero Hematopoietic Cell Transplantation Safe in Fetuses with Alpha Thalassemia Major

In utero hematopoietic cell transplantation (IUHCT) with maternal cells was safe in two fetuses with alpha thalassemia major (ATM), according to interim results of...
On location

Adding Venetoclax to Cladribine and Cytarabine Backbone Improves Response Rates, Outcomes in Older Patients...

The addition of the BCL2 inhibitor venetoclax (alternating with the hypomethylating agent azacitidine) to a low-intensity backbone combination of cladribine with low-dose cytarabine (CLAD/LDAC)...
Advertisement

Current Issue

May 2021 Volume 7 Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Block title